Voio Raises $8.6M Seed Round to Bring Unified AI Platform to Radiology
Voio, a Berkeley, California–based healthcare artificial intelligence company, has emerged from stealth after raising $8.6 million in seed funding to accelerate development of its AI-powered radiology platform. The financing marks a significant milestone for the company as it moves to commercialize technology designed to help radiologists interpret medical scans more accurately and efficiently while reducing workflow friction across imaging departments.
The seed round was led by Laude Ventures and The House Fund, two venture capital firms known for backing technically ambitious startups emerging from leading research institutions. Investors are supporting Voio’s vision to build a unified AI system that can analyze complete imaging studies, generate high-quality draft reports, and integrate directly into clinical workflows used by radiology teams.
Voio was founded by a group of prominent researchers and clinicians from the University of California system. The founding team includes Adam Yala, an assistant professor of computational precision health at UC Berkeley and UC San Francisco; Dr Maggie Chung, an assistant professor of radiology and biomedical imaging at UCSF and a practicing radiologist; and Trevor Darrell, a professor of computer science at UC Berkeley and founder of the Berkeley AI Research Lab. Together, the founders bring deep expertise across machine learning, computer vision and frontline clinical practice.
The company is targeting radiology, a specialty facing mounting pressure as the volume of medical imaging continues to grow worldwide, while radiologist capacity remains constrained. Imaging professionals frequently navigate multiple disconnected software systems, including image viewers, reporting tools and electronic health records. This fragmentation can slow interpretation, lengthen turnaround times and contribute to clinician burnout. Voio’s platform aims to consolidate these functions into a single AI-powered environment.
At the center of Voio’s technology is a vision-language model designed to interpret complex imaging data such as CT and MRI scans. The company has released its first open-source model, called Pillar-0, which it says outperforms existing publicly available models on several imaging benchmarks. Rather than analyzing images in isolation, the system evaluates entire studies and produces structured, clinically relevant draft reports for radiologists to review and finalize.
Voio’s decision to open-source Pillar-0 reflects a broader strategy focused on transparency and trust in medical AI. By making its foundational model available to the research and clinical communities, the company aims to encourage independent validation, faster iteration and broader collaboration in a field where accuracy and accountability are essential. Voio plans to layer proprietary workflow tools and integrations on top of this open foundation.
The newly raised capital will be used to expand the company’s research and engineering teams, advance product development and support early deployments with healthcare providers. Voio plans to scale its unified reading platform, deepen integrations with hospital systems and continue refining its models using diverse clinical data. The company’s long-term goal is to reduce time spent on repetitive tasks, enabling radiologists to focus on complex diagnostic decisions and patient care.
For investors, the opportunity extends beyond incremental gains in diagnostic accuracy. Both Laude Ventures and The House Fund are backing Voio’s ambition to reshape radiology’s infrastructure, embedding AI directly into daily workflows rather than offering it as a standalone tool. As healthcare systems seek ways to improve efficiency without compromising quality, Voio is positioning itself as a key player in the next generation of AI-driven clinical platforms.
With its seed funding secured, Voio is moving from research-driven development toward broader clinical adoption. Observers note that success in radiology could open the door to similar workflow-focused AI platforms in other medical specialties, potentially establishing Voio as a foundational company in healthcare artificial intelligence.
